Combined Analysis of Phase III Trials Evaluating [(99m)Tc]Tilmanocept and Vital Blue Dye for Identification of Sentinel Lymph Nodes in Clinically Node-Negative Cutaneous Melanoma

BACKGROUND: [(99m)Tc]Tilmanocept is a CD206 receptor-targeted radiopharmaceutical designed for sentinel lymph node (SLN) identification. Two nearly identical nonrandomized phase III trials compared [(99m)Tc]tilmanocept to vital blue dye. METHODS: Patients received [(99m)Tc]tilmanocept and blue dye....

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Sondak, Vernon K., King, Dennis W., Zager, Jonathan S., Schneebaum, Schlomo, Kim, Julian, Leong, Stanley P. L., Faries, Mark B., Averbook, Bruce J., Martinez, Steve R., Puleo, Christopher A., Messina, Jane L., Christman, Lori, Wallace, Anne M.
Format: Artigo
Sprache:Inglês
Veröffentlicht: Springer-Verlag 2012
Schlagworte:
Melanomas
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3560941/
https://ncbi.nlm.nih.gov/pubmed/23054107
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1245/s10434-012-2612-z
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge